Browse by All Cardiff Authors
Number of items: 6.
Capper, Rebecca, Britt-Compton, Bethan, Tankimanova, Maira, Rowson, Janet Maud, Letsolo, Boitelo, Man, Stephen Tzekwung ORCID: https://orcid.org/0000-0001-9103-1686, Haughton, Michele Fleur and Baird, Duncan Martin ORCID: https://orcid.org/0000-0001-8408-5467
2007.
The nature of telomere fusion and a definition of the critical telomere length in human cells.
Genes and Development
21
(19)
, pp. 2495-2508.
10.1101/gad.439107
|
|
Skinner, Julia, Bounacer, Ali, Bond, Jane Ann, Haughton, Michele Fleur, deMicco, Catherine and Wynford-Thomas, David
2004.
Opposing effects of mutant ras oncoprotein on human fibroblast and epithelial cell proliferation: implications for models of human tumorigenesis.
Oncogene
23
(35)
, pp. 5994-5999.
10.1038/sj.onc.1207798
|
|
Preto, Ana, Singhrao, Simarjit Kaur, Haughton, Michele Fleur, Kipling, David Glyn, Wynford-Thomas, David and Jones, Christopher John
2004.
Telomere erosion triggers growth arrest but not cell death in human cancer cells retaining wild-type p53: implications for antitelomerase therapy.
Oncogene
23
(23)
, pp. 4136-4145.
10.1038/sj.onc.1207564
|
|
Davis, Terence ORCID: https://orcid.org/0000-0003-2780-0262, Singhrao, Simarjit Kaur, Wyllie, Fiona Sandra, Haughton, Michele Fleur, Smith, Paul James, Wiltshire, Marie, Wynford-Thomas, David, Jones, Christopher John, Faragher, Richard G. A. and Kipling, David Glyn
2003.
Telomere-based proliferative lifespan barriers in Werner-syndrome fibroblasts involve both p53-dependent and p53-independent mechanisms.
Journal of Cell Science (JCS)
116
(7)
, pp. 1349-57.
10.1242/jcs.00331
|
|
Stephens, Philip ORCID: https://orcid.org/0000-0002-0840-4996, Cook, Helen, Hilton, Joanne, Jones, Christopher John, Haughton, Michele Fleur, Wyllie, Fiona Sandra, Skinner, Julia W., Harding, Keith Gordon, Kipling, David Glyn and Thomas, David William ORCID: https://orcid.org/0000-0001-7319-5820
2003.
An analysis of replicative senescence in dermal fibroblasts derived from chronic leg wounds predicts that telomerase therapy would fail to reverse their disease-specific cellular and proteolytic phenotype.
Experimental Cell Research
283
(1)
, pp. 22-35.
10.1016/S0014-4827(02)00021-6
|
|
This list was generated on Tue Apr 15 08:29:24 2025 BST.